Skip to content

Simultaneous hybird (Endo/Epicardial) procedure for persistent and long-standing persistent atiral fibrillation

Simultaneous hybird (Endo/Epicardial) procedure for persistent and long-standing persistent atiral fibrillation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-16009735
Enrollment
Unknown
Registered
2016-11-04
Start date
2016-10-12
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

four cohorts:Simultaneous hybird (Endo/Epicardial) procedure for persistent and long-standing persistent atiral fibrillation

Sponsors

Shanghai Jiao Tong University Affiliated Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Younger than 75 years of age, more than 18 years of age; 2. persistent atrial fibrillation duration of more than 1 week; 3. long-lasting persistent atrial fibrillation, atrial fibrillation time more than 1 year; 4. left atrial diameter less than 60mm; 5. cardiac function NYHA-II level, and EF greater than 40% or more; 6. 1 month after stroke, muscle strength in patients with more than 4, and sanity clear; 7. The investigator agreed to participate in the clinical trial and sign informed consent, and agreed to follow the proof program requirements for follow-up evaluation.

Exclusion criteria

Exclusion criteria: 1. hyperthyroidism caused by atrial fibrillation, hyperthyroidism is not controlled before; 2. rheumatic valvular disease caused by atrial fibrillation; 3. atrial fibrillation caused by congenital heart disease; 4. pulmonary heart disease and pulmonary hypertension in patients with atrial fibrillation; 5. patients with cardiomyopathy complicated by atrial fibrillation; 6. have acute or severe systemic infection; 7. previous CABG (CABG) and valve replacement surgery and other thoracotomy; 8. have obvious bleeding tendency and blood system diseases; 9. aortic dissection or aortic aneurysm patients; 10. malignant tumors and end-stage disease patients; 11. patients with any other condition considered unsuitable to participate in the trial; 12. Researchers from the medical ethics point of view it is necessary to terminate the study of patients.

Design outcomes

Primary

MeasureTime frame
DCG;echocardiography;Cardiac electrophysiological examination;

Secondary

MeasureTime frame
Pulmonary vein CT;Blood biochemical examination;Esophageal ultrasound;

Countries

China

Contacts

Public ContactLi feng

Shanghai Jiao Tong University Affiliated Shanghai Sixth People's Hospital

15800591362@163.com+86 15800591362

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026